Will Ambry Genetics Acquisition Drive Tempus AI's Prospects? [Yahoo! Finance]
Tempus AI, Inc. - Class A (TEM)
Company Research
Source: Yahoo! Finance
This acquisition will likely help Tempus revolutionize healthcare by integrating cutting-edge genetic testing with AI-driven insights, especially testing capabilities for inherited cancer risk. Per the acquisition deal, Tempus AI's total consideration for Ambry includes $375 million in cash and $225 million in equity. The deal is anticipated to be closed in the first quarter of 2025. By acquiring Ambry, Tempus can better support healthcare teams from early diagnosis to ongoing patient management, reinforcing its role as a leader in precision medicine. The deal will likely drive TEM's prospects as it targets a lucrative cancer market. The company's shares have surged 45.6% so far this year against the industry's decline of 13.2%. The S&P 500 Index has risen 25.4% in the same period. Image Source: Zacks Investment Research Ambry Genetics, headquartered in Aliso Viejo, CA, is a pioneer in genetic testing with a mission to enhance health outcomes by elucidating the relationship
Show less
Read more
Impact Snapshot
Event Time:
TEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEM alerts
High impacting Tempus AI, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
TEM
News
- Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare SolutionsBusiness Wire
- New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device [Yahoo! Finance]Yahoo! Finance
- Why Healthcare Providers Are Increasingly Trusting Artificial Intelligence for Detection & DiagnosisGlobeNewswire
- New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF DeviceBusiness Wire
- Tempus AI, Inc. (NASDAQ: TEM) had its price target raised by analysts at Bank of America Co. from $52.00 to $54.00. They now have a "neutral" rating on the stock.MarketBeat
TEM
Earnings
- 11/4/24 - Miss
TEM
Sec Filings
- 12/20/24 - Form 4
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- TEM's page on the SEC website